Corporate Information
-
21 Oct, 2024
Valberedning utsedd inför Spago Nanomedicals årsstämma 2025
-
21 Oct, 2024
Nomination committee appointed for Spago Nanomedical’s Annual General Meeting 2025
-
1 Oct, 2024
Spago Nanomedical i ny fas med fullt fokus på Tumorad-programmet
-
1 Oct, 2024
Spago Nanomedical in new phase with full focus on the Tumorad program
-
27 Aug, 2024
Spago Nanomedicals fas I/IIa-studie Tumorad-01 fortsätter efter framgångsrikt slutförd behandling av första patientgruppen
-
27 Aug, 2024
Spago Nanomedical’s Phase I/IIa study Tumorad-01 continues following successful treatment completion of first patient group
-
10 Jun, 2024
Kommuniké från årsstämma 2024 i Spago Nanomedical AB
-
10 Jun, 2024
Bulletin from the 2024 Annual General Meeting of Spago Nanomedical AB
-
20 May, 2024
Spago Nanomedical uppdaterar om Tumorad-01 – studien framskrider enligt plan
-
20 May, 2024
Spago Nanomedical provides an update on Tumorad-01 – trial proceeds as planned